IL-17 Blockade in Psoriasis

descriptionPublicationkeyboard_double_arrow_right Article 01 Dec 2016 English Publisher:Elsevier BVJournal:Cell, volume 167, page 1,669 (issn: 0092-8674,

Copyright policy )

Authors: Patrick R, Burkett; Vijay K, Kuchroo;

doi: 10.1016/j.cell.2016.11.044

pmid: 27984714

IL-17 Blockade in Psoriasis

- Summary
- Subjects
- Metrics

Abstract

IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

Related Organizations

Brigham and Women's Faulkner Hospital
United States

Keywords

Interleukin-17, Antibodies, Monoclonal, Humans, Psoriasis, Antibodies, Monoclonal, Humanized

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	54
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%